UK's SkinBioTherapeutics probes former CEO, issues fiscal 2026 profit warning
Feb 16 (Reuters) - British skin-health company SkinBioTherapeutics SBTX.L said on Monday it was investigating its former CEO and believes he misrepresented material financial information to the board and auditors. The company said the resulting restatement of accounts would mean fiscal 2026 results would be "significantly below" market expectations. (Reporting by Ankita Bora in Bengaluru; Editing by Rashmi Aich) ((Ankita.Bora@thomsonreuters.com;))
Recent news on Skinbiotherapeutics
See all newsBrief: SkinBioTherapeutics Appoints Rachel Parsonage As CEO & Alyson Levett As Chair On Permanent Basis
SkinBioTherapeutics - Trading Statement
Brief: SkinBioTherapeutics Appoints Anita Slater To Start As Interim CFO
SkinBioTherapeutics - Appointment of Interim CFO
SkinBioTherapeutics - Holding(s) in Company